Sugiura Keita, Masumoto Akane, Tachibana Haruki, Tatsumi Yoshiyuki
Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.
J Fungi (Basel). 2021 Mar 12;7(3):208. doi: 10.3390/jof7030208.
To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for and (8 each, with a total of 16 strains) were determined using the microdilution checkerboard technique based on the Clinical and Laboratory Standard Institute guidelines. No antagonism was observed between the topical and oral drugs against all the tested strains. Efinaconazole with terbinafine exerted a synergistic effect on 43.8% of the strains tested (7/16 strains) and efinaconazole with itraconazole on 12.5% (2/16 strains). Conversely, luliconazole showed no synergistic effect with terbinafine but was synergistically effective with itraconazole against 31.3% of the strains (5/16 strains). Tavaborole showed no synergistic effect with terbinafine and was synergistically effective with itraconazole against 18.8% of the strains (3/16 strains). The results suggest that a combination of topical and oral drugs could be a potential clinical option for onychomycosis treatment, and overall, the efinaconazole and oral drug combination would be the most advantageous among the tested combinations.
为评估抗甲癣药物的联合作用,根据临床和实验室标准协会指南,采用微量稀释棋盘法测定了局部用药(艾氟康唑、卢立康唑和他氟硼酸盐)和口服药物(伊曲康唑和特比萘芬)对 和 (各8株,共16株菌株)的最低抑菌浓度。在所有测试菌株中,未观察到局部用药和口服药物之间存在拮抗作用。艾氟康唑与特比萘芬对43.8%的测试菌株(7/16株)发挥协同作用,艾氟康唑与伊曲康唑对12.5%的测试菌株(2/16株)发挥协同作用。相反,卢立康唑与特比萘芬未显示协同作用,但与伊曲康唑对31.3%的菌株(5/16株)发挥协同作用。他氟硼酸盐与特比萘芬未显示协同作用,与伊曲康唑对18.8%的菌株(3/16株)发挥协同作用。结果表明,局部用药和口服药物联合使用可能是治疗甲癣的一种潜在临床选择,总体而言,在测试的联合用药中,艾氟康唑与口服药物联合使用最为有利。